FDA panel recommends approving MannKind's Afrezza

|About: MannKind Corporation (MNKD)|By:, SA News Editor

The FDA's advisory committee voted 13-1 to recommend Afrezza be given marketing approval for treating type 1 diabetes, and 14-0 for treating type 2 diabetes. The PDUFA date for the FDA to complete its review of Afrezza is set for April 15.

MannKind (MNKD) shares were halted all day, and remain halted AH. The company notes Afrezza, if approved, would be "the first ultra rapid-acting mealtime insulin therapy available in the United States."